Comparison of Sensitivity of Enzyme Immunoassays for Toxin A and B in different C. difficile PCR Ribotypes

被引:0
|
作者
Lee, Yangsoon [1 ,2 ,3 ]
Kim, Myungsook [1 ,2 ]
Kim, Heejung [1 ,2 ]
Lee, Kyungwon [1 ,2 ]
机构
[1] Yonsei Univ, Coll Med, Dept Lab Med, Seoul 120752, South Korea
[2] Yonsei Univ, Coll Med, Res Inst Bacterial Resistance, Seoul 120752, South Korea
[3] Ilsan Hosp, Natl Hlth Insurance Serv, Dept Lab Med, Ilsan, South Korea
来源
基金
新加坡国家研究基金会;
关键词
MOLECULAR EPIDEMIOLOGY; SOUTH-KOREA; INFECTIONS; RESISTANCE; TESTS;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Enzyme immunoassays (EIAs) for toxins A and B are the most common assays for the diagnosis of Clostridium difficile infection due to their rapidity and ease of use. However, the sensitivity of different kits varies greatly. The predominant PCR ribotypes of C. difficile vary according to the region or country studied, and it was recently reported that the sensitivity of EIAs can be affected by the strain type. The aim of this study was to assess the sensitivity of EIAs in different PCR ribotypes of C. difficile during a period of five years in a Korean hospital. A total of 969 toxigenic C. difficile isolates were recovered from patients with diarrhea in a hospital from 2006 to 2009 (inclusive), and 2011. Overall sensitivities of Tox A/B Quik Chek (TechLab, Blacksburg, VA) and VIDAS C. difficile A & B (bioMerieux, Marcy l'Etoile, France) were 36.4% and 46.3%, respectively. The sensitivities of TOX A/B Quick Chek and VIDAS Clostridium difficile A & B for the five most common ribotypes were as follows: 56.6% and 71.7% for ribotype AB17 (ribotype 018); 48.6% and 54.3% for ribotype aB (ribotype 017); 25.3% and 36.3% for ribotype AB2 (ribotype 014); 13.0% and 24.2% for ribotype AB3; 66.7% and 0% for ribotype AB17 (ribotype 001), respectively. The sensitivity for the predominant ribotype, AB17, was significantly different from those for aB, AB2, AB1, and AB3 using VIDAS Clostridium difficile A & B (p<0.05). These data suggest that the sensitivity of EIA may be affected by the distribution of ribotypes.
引用
收藏
页码:38 / 41
页数:4
相关论文
共 50 条
  • [41] Comparison of the Verigene Clostridium difficile, Simplexa C. difficile Universal Direct, BD MAX Cdiff, and Xpert C. difficile assays for the detection of toxigenic C. difficile
    Gilbreath, Jeremy J.
    Verma, Punam
    Abbott, April N.
    Butler-Wu, Susan M.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2014, 80 (01) : 13 - 18
  • [42] Erratum to: Role of fecal Clostridium difficile load in discrepancies between toxin tests and PCR: is quantitation the next step in C. difficile testing?
    J. L. Leslie
    S. H. Cohen
    J. V. Solnick
    C. R. Polage
    European Journal of Clinical Microbiology & Infectious Diseases, 2012, 31 (12) : 3301 - 3301
  • [43] Synthesis and SAR studies of novel benzodiazepinedione-based inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB)
    Letourneau, Jeffrey J.
    Stroke, Ilana L.
    Hilbert, David W.
    Cole, Andrew G.
    Sturzenbecker, Laurie J.
    Marinelli, Brett A.
    Quintero, Jorge G.
    Sabalski, Joan
    Li, Yanfang
    Ma, Linh
    Pechik, Igor
    Stein, Philip D.
    Webb, Maria L.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (23-24) : 3601 - 3605
  • [44] Simultaneous Detection of Clostridioides difficile Glutamate Dehydrogenase and Toxin A/B: Comparison of the C. DIFF QUIK CHEK COMPLETE and RIDASCREEN Assays
    Yoo, In Young
    Song, Dong Joon
    Huh, Hee Jae
    Lee, Nam Yong
    ANNALS OF LABORATORY MEDICINE, 2019, 39 (02) : 214 - 217
  • [45] Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model
    Freeman, Jane
    Baines, Simon D.
    Saxton, Katie
    Wilcox, Mark H.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (01) : 83 - 91
  • [46] A Human Gut Ecosystem Protects Against C. difficile Disease and Decreases Inflammation by Targeting C. difficile Toxin tcdA
    Martz, Sarah
    He, Shu-Mei
    Noordhof, Curtis
    Hurlbut, David J.
    Allen-Vercoe, Emma
    Sun, Jun
    Claud, Erika
    Petrof, Elaine O.
    GASTROENTEROLOGY, 2016, 150 (04) : S748 - S748
  • [47] Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection With Greater Severity and Higher Recurrence Rates
    Guh, Alice Y.
    Hatfield, Kelly M.
    Winston, Lisa G.
    Martin, Brittany
    Johnston, Helen
    Brousseau, Geoffrey
    Farley, Monica M.
    Wilson, Lucy
    Perlmutter, Rebecca
    Phipps, Erin C.
    Dumyati, Ghinwa K.
    Nelson, Deborah
    Hatwar, Trupti
    Kainer, Marion A.
    Paulick, Ashley L.
    Karlsson, Maria
    Gerding, Dale N.
    McDonald, L. Clifford
    CLINICAL INFECTIOUS DISEASES, 2019, 69 (10) : 1667 - 1674
  • [48] Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients
    Erb, S.
    Frei, R.
    Stranden, A. M.
    Dangel, M.
    Tschudin-Sutter, S.
    Widmer, A. F.
    CLINICAL MICROBIOLOGY AND INFECTION, 2015, 21 (11) : 998.e9 - 998.e15
  • [49] The C. difficile toxin B membrane translocation machinery is an evolutionarily conserved protein delivery apparatus
    Kathleen E. Orrell
    Michael J. Mansfield
    Andrew C. Doxey
    Roman A. Melnyk
    Nature Communications, 11
  • [50] The C. difficile toxin B membrane translocation machinery is an evolutionarily conserved protein delivery apparatus
    Orrell, Kathleen E.
    Mansfield, Michael J.
    Doxey, Andrew C.
    Melnyk, Roman A.
    NATURE COMMUNICATIONS, 2020, 11 (01)